| pubmed-article:3463363 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3463363 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:3463363 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:3463363 | lifeskim:mentions | umls-concept:C0544452 | lld:lifeskim |
| pubmed-article:3463363 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3463363 | pubmed:dateCreated | 1986-11-12 | lld:pubmed |
| pubmed-article:3463363 | pubmed:abstractText | Twenty-seven consecutive patients with previously untreated, or minimally treated benign phase Philadelphia-chromosome-positive, chronic myelogenous leukaemia (CML) were treated with partially purified human leucocyte (alpha) interferon; 24 of the 27 patients responded to therapy achieving either haematological remission (20 patients) or partial haematological remission (four patients). In the responding patients the peripheral white blood cells declined from a median of 89.6 X 10 X 10(9)/l to 4.5 X 10 X 10(9)/l. The serum lactate dehydrogenase declined from a mean of 8.36 Katal/l (492 mu/ml) to 2.8 Katal/l (165 mu/ml), and the vitamin B12 levels declined from 1492 pg/ml to 838 pg/ml. Fifteen patients had splenomegaly. The spleen size normalized in four and decreased by a median of 30% in 10 additional patients. The bone marrow cellularity fell from a median of 100% to a median of 62%. In seven of the 24 responding patients, followed for greater than or equal to 6 months, the percentage of Ph1-positive cells in the bone marrow declined to a median of 70% (range 5-75%). Alpha interferon was found to be an effective therapeutic agent for controlling the myeloid proliferation in CML, and in partially restoring the nonclonal haematopoietic cells in some of the patients. | lld:pubmed |
| pubmed-article:3463363 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3463363 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3463363 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3463363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3463363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3463363 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3463363 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3463363 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:3463363 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:3463363 | pubmed:author | pubmed-author:TrujilloJJ | lld:pubmed |
| pubmed-article:3463363 | pubmed:author | pubmed-author:KeatingMM | lld:pubmed |
| pubmed-article:3463363 | pubmed:author | pubmed-author:TalpazMM | lld:pubmed |
| pubmed-article:3463363 | pubmed:author | pubmed-author:McCredieKK | lld:pubmed |
| pubmed-article:3463363 | pubmed:author | pubmed-author:GuttermanJJ | lld:pubmed |
| pubmed-article:3463363 | pubmed:author | pubmed-author:KantarjianHH | lld:pubmed |
| pubmed-article:3463363 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3463363 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:3463363 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3463363 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3463363 | pubmed:pagination | 87-95 | lld:pubmed |
| pubmed-article:3463363 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:meshHeading | pubmed-meshheading:3463363-... | lld:pubmed |
| pubmed-article:3463363 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3463363 | pubmed:articleTitle | Chronic myelogenous leukaemia: haematological remissions with alpha interferon. | lld:pubmed |
| pubmed-article:3463363 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3463363 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3463363 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3463363 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3463363 | lld:pubmed |
